Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Sarcoma 1

Conditions

Lung Neoplasms 1

Interventions

Carboplatin 351pembrolizumab 326Pemetrexed 250Cisplatin 221Paclitaxel 149Nivolumab 139durvalumab 134osimertinib 112Docetaxel 112atezolizumab 109Specimen Handling 91Radiotherapy 88Drug Therapy 87Magnetic Resonance Spectroscopy 77Etoposide 77Radiosurgery 74Gemcitabine 72Ipilimumab 55130-nm albumin-bound paclitaxel 54Bevacizumab 53cemiplimab 47tislelizumab 46Blood Specimen Collection 42Cetuximab 35Taxes 34Platinum 33Injections 33Biopsy 33Standard of Care 32Immunoglobulin G 30

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
mocetinostat × Thoracic × 1 year × Clear all
NCT03220477 2025-08-06

Pembrolizumab (Immunotherapy Drug) in Combination With Guadecitabine and Mocetinostat (Epigenetic Drugs) for Patients With Advanced Lung Cancer.

Memorial Sloan Kettering Cancer Center

Phase 1 Active not recruiting
28 enrolled
Thoracic

Lung Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡